Histone deacetylase inhibitors effect on CXCR4 CXCL12 chemokine axis in cancer metastasis

Abstract

Aim: We aimed to investigate the cytotoxicity and antimetastatic effect of histone deacetylase inhibitors (HDACi) on Human T lymphocyte cells (Jurkat), Human leukaemia cells (HL60) and Human monocyte cells (THP-1). We chose six HDACi in this study: Panopinostat, Entinostat, Tubastatin, PCI-34051, CHDI00390576 and RGFP 966. Method: Cytotoxicity (MTS) assay, chemoattractant assay, immunofluorescence staining assay and flow cytometry analysis were performed to investigate the cytotoxicity, antimetastatic and CXCR4 receptor expression regulation effect of these agents on cancer cell lines. Findings: Our finding concludes that HDAC inhibitors' cytotoxicity varies and depends on the dose, time, and cell line used. Also, HDAC inhibitors did not prevent cancer cell migration through CXCR4/CXCL12 chemokine axis. In addition, Immunofluorescence staining showed no changes in CXCR4 receptor expression in cell surface after HDAC inhibitors treatment. Supporting this finding, flow cytometry analysis (FC) after HDAC inhibitors treatment showed no CXCR4 receptor expression changes.